Randall E. Woods
CEO
Pharmaceutical
Sophiris Bio
United States of America
Biography
Randall E. Woods joined Sophiris as Chief Executive Officer in August 2012 and a member of our board of directors since October 2012 and brings with him more than 40 years of biotech and pharmaceutical leadership experience. Prior to joining Sophiris, Mr. Woods was President and CEO of Sequel Pharmaceuticals, a spin-out of NovaCardia developing a potential treatment for atrial fibrillation. Mr. Woods was previously the President and CEO of NovaCardia, a pharmaceutical company focused on cardiovascular diseases until its acquisition by Merck & Co for $350 million in 2007. Prior to NovaCardia, Mr. Woods was President and CEO of Corvas International, a publicly held biopharmaceutical company focused on cardiovascular disease and cancer until its acquisition by Dendreon in 2003. Before joining Corvas, he served as President of Boehringer Mannheim’s U.S.
Research Interest
Pharmaceutical
